This database contains 1231 studies, archived under the term: "humans"
Click here to filter this large number of results.
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study
Simioni, S.,
Cavassini, M.,
Annoni, J.-M.,
Metral, M.,
Iglesias, K.,
Rimbault Abraham, A.,
Jilek, S.,
Calmy, A.,
Muller, H.,
Fayet-Mello, A.,
Giacobini, E.,
Hirschel, B.,
Du Pasquier, R. A.
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.; Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by […]
Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death
Sierra, Saleta,
Ramos, Maria C.,
Molina, Pilar,
Esteo, Cynthia,
Vázquez, Jose Antonio,
Burgos, Javier S.
There is growing evidence to support the hypothesis that statins may act as neuroprotectants in several neuropathological conditions, including Alzheimer’s disease. The mechanisms for neuroprotection are only partially understood, however, and pleiotropic phenomena could be involved. We have made a comparative study of 9 statins (lovastatin, mevastatin, pravastatin, simvastatin, cerivastatin, atorvastatin, fluvastatin, pitavastatin, and rosuvastatin), […]
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET
Shokouhi, S.,
Claassen, D.,
Kang, H.,
Ding, Z.,
Rogers, B.,
Mishra, A.,
Riddle, W. R.
Unlabelled: Evaluating the symptomatic progression of mild cognitive impairment (MCI) caused by Alzheimer disease (AD) is practically accomplished by tracking performance on cognitive tasks, such as the Alzheimer Disease Assessment Scale’s cognitive subscale (ADAS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ). The longitudinal relationships between cognitive decline and metabolic function as […]
A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease
Shinto, Lynne,
Quinn, Joseph,
Montine, Thomas,
Dodge, Hiroko H.,
Woodward, William,
Baldauf-Wagner, Sara,
Waichunas, Dana,
Bumgarner, Lauren,
Bourdette, Dennis,
Silbert, Lisa,
Kaye, Jeffrey
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer’s disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid […]
A randomized controlled trial of estrogen treatment in men with mild cognitive impairment
This randomized, placebo-controlled, cross-over study investigated whether estrogen treatment would have a beneficial effect on tests of verbal memory in men with mild cognitive impairment (MCI). Forty-three men newly diagnosed with MCI were administered a battery of neuropsychological tests before randomly receiving 12 weeks of treatment with estrogen or placebo followed by a 12 week […]
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Shaw, Leslie M.,
Vanderstichele, Hugo,
Knapik-Czajka, Malgorzata,
Figurski, Michal,
Coart, Els,
Blennow, Kaj,
Soares, Holly,
Simon, Adam J.,
Lewczuk, Piotr,
Dean, Robert A.,
Siemers, Eric,
Potter, William,
Lee, Virginia M.-Y.,
Trojanowski, John Q.
The close correlation between abnormally low pre-mortem cerebrospinal fluid (CSF) concentrations of amyloid-β1-42 (Aβ(1-42)) and plaque burden measured by amyloid imaging as well as between pathologically increased levels of CSF tau and the extent of neurodegeneration measured by MRI has led to growing interest in using these biomarkers to predict the presence of AD plaque […]
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study
Shatunov, Aleksey,
Mok, Kin,
Newhouse, Stephen,
Weale, Michael E,
Smith, Bradley,
Vance, Caroline,
Johnson, Lauren,
Veldink, Jan H,
van Es, Michael A,
van den Berg, Leonard H.,
Robberecht, Wim,
Van Damme, Philip,
Hardiman, Orla,
Farmer, Anne E,
Lewis, Cathryn M,
Butler, Amy W,
Abel, Olubunmi,
Andersen, Peter M,
Fogh, Isabella,
Silani, Vincenzo,
Chiò, Adriano,
Traynor, Bryan J,
Melki, Judith,
Meininger, Vincent,
Landers, John E,
McGuffin, Peter,
Glass, Jonathan D,
Pall, Hardev,
Leigh, P Nigel,
Hardy, John,
Brown, Robert H,
Powell, John F,
Orrell, Richard W,
Morrison, Karen E,
Shaw, Pamela J,
Shaw, Christopher E,
Al-Chalabi, Ammar
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons that results in progressive weakness and death from respiratory failure, commonly within about 3 years. Previous studies have shown association of a locus on chromosome 9p with ALS and linkage with ALS-frontotemporal dementia. We aimed to test whether this genomic region is also […]
Relation of hemoglobin to level of cognitive function in older persons
Shah, Raj C.,
Wilson, Robert S.,
Tang, Yuxiao,
Dong, Xinqi,
Murray, Anne,
Bennett, David A.
Background: While decreased hemoglobin concentration is common in the elderly, the relationship of the entire range of hemoglobin concentrations with cognitive function is not well understood.; Methods: Cross-sectional analyses were conducted utilizing data from community-dwelling, older persons participating in the Rush Memory and Aging Project. Proximate to first available hemoglobin measurement, 21 cognitive tests were […]